Mifegyne (Mifepristone)

Mifepristone acts as a competitive antagonist at progesterone receptors. By blocking progesterone’s action, it causes the uterine lining to break down and the embryo to detach, while also sensitising the uterus to prostaglandins that promote expulsion. In adrenal tissue, the same blockade can reduce cortisol synthesis.

The specific dose and regimen of Mifegyne are determined by the prescribing clinician based on the indication, gestational age and local medical guidelines. Patients should follow the exact instructions provided by their qualified health‑care professional.

Mifegyne is contraindicated in pregnancy beyond the intended medical termination and should not be used during ongoing pregnancy. It is also not recommended for breastfeeding mothers because the drug can be excreted in breast milk and may affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The most common partner drug is misoprostol, a prostaglandin analogue. Mifegyne initiates uterine lining breakdown, while misoprostol induces uterine contractions to complete expulsion. Together they provide a highly effective regimen, whereas misoprostol alone is less effective for early medical abortion.

Mifegyne tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid exposure to extreme heat or humidity.

Mifegyne is supplied as an oral tablet and is taken by mouth under medical supervision. The tablet is usually administered in a clinical setting after confirming gestational age and eligibility, followed by a scheduled follow‑up to assess the outcome.

Serious adverse events include heavy hemorrhage, severe infection that may lead to sepsis, and allergic reactions such as rash, swelling or anaphylaxis. Patients should seek immediate medical attention if they experience excessive bleeding, fever, severe abdominal pain or signs of an allergic response.

Mifegyne should not be used by individuals with a confirmed or suspected ectopic pregnancy, chronic adrenal insufficiency, uncontrolled hypertension, or known hypersensitivity to mifepristone. It is also contraindicated beyond ten weeks gestation and in patients who are unable to undergo appropriate medical follow‑up.